2

The Degree of Atherosclerosis and the Metabolic Characteristics according to the Abdominal Obesity in Type 2 Diabetic Patients

Chul Sik Kim, Jong Suk Park, Joo Young Nam, Jina Park, Min Ho Cho, Ji Sun Nam, Dol Mi Kim, Soo Jee Yoon, Jae Hyun Nam, Chul Woo Ahn, Bong Soo Cha, Sung Kil Lim, Kyung Rae Kim, Hyun Chul Lee

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

- Abstract -

Background: Many of the maturity-onset type 2 diabetic patients with hypertension and dyslipidemia in Korea are not associated with obesity. However, these patients are at risk for developing macrovascular complications such as atherosclerosis due to hyperinsulinemia, insulin resistance and abdominal obesity. The aims of this study were to compare the clinical and biochemical differences between the type 2 diabetic patients that are with and without abdominal obesity, and we also wished to investigate the degree of insulin resistance and atherosclerosis in these patients.

Methods: Among 530 type 2 diabetes mellitus (DM) patients, the percentages of under-weight (UW), normal-weight (NW), over-weight (OW) and obese (OB) (BMI <20, 20-25, 25-29.9 and 30, respectively) subjects were 8.9%, 62.1%, 25.1% and 3.9%, respectively. To evaluate the severity of their atherosclerosis, the coronary artery calcification (CAC) score was measured by electron beam computed tomography, and the intima-media thickness (IMT) of the common carotid artery and the ankle-brachial pressure index (ABPI) were also measured. The Insulin sensitivity index (ISI) was measured by the plasma glucose disappearance rate (kitt: %/min).

Results: 1. There were no differences in age, duration of DM and the HbA_{1c} levels according to BMI for both the men and women, but the waist-hip ratio (WHR) and systolic blood pressure (SBP) were significantly different among each group.

^{: 2003 10 31 , : 2004 10 18 , : ,}

Serum triglyceride (TG), HDL-cholesterol (HDL-C), free fatty acid (FFA), fibrinogen, and fasting c-peptide levels, {excluding total cholesterol (TC)}, were also significantly different. The ISI, which is a marker for insulin resistance, as well correlated with the patients' BMI. Subjects having an with ISI above 2.5%/min were considered as having insulin resistance, and 28%, 60%, 68% and 75% of patients in the UW, NW, OW and OB groups, respectively, demonstrated insulin resistance. The visceral fat area/subcutaneous fat area ratio and visceral fat area/thigh muscle area ratio also increased with BMI.

- 2. The median values of the WHR were 0.95 for the men and 0.91 for the women. There were no significant differences for age, BMI, duration of DM and HbA_{1c} between patients with and without abdominal obesity, but the SBP, TG, HDL-C, FFA, fibrinogen and ISI were significantly different between those two groups.
- 3. For the OW group as well as the NW group, the carotid IMT, ABPI and CAC scores were significantly different between the patients with and without abdominal obesity. However, there were no differences between the NW group and the OW group.

Conclusion: In conclusion, those patients with abdominal obesity, regardless of their BMIs, have a higher prevalence for atherosclerosis, dyslipidemia, and hypertension, compared to those patients without abdominal obesity. Therefore, it is important to screen for atherosclerosis and to manage it accordingly, for the patients with insulin resistance or abdominal obesity in order to decrease their risk of developing atherosclerotic events (J Kor Diabetes Assoc 28:377 ~ 391, 2004).

Key Words: Abdominal obesity, Insulin resistance, Type 2 diabetes, Atherosclerosis

18) bitor - 1 (PAI - 1) 가 가 가 가 가 30 kg/m² 25 kg/m² 19) 가 1988 Reaven¹⁾ 가 20) . Ruderman 가 가 2~17) (metabolic obesity) fibrinogen plasminogen activator inhi-

	tolerance test) 20G	32)	12
,	3-way		
가	,		,
가 .	20G		
	·	가	
가 ^{21,22)} .	20-30		
,	heating pad		
22 24)	60~70		100
23~31)	(Hu	ımulin-R, Eli	i Lilly, USA)
	1 kg 0	.1	
2		0, 3, 6, 9, 1	12, 15
가 가			15
71	20% 100 ml	_	. Beck-
·	man glucose analyzer I erton, CA, USA)	l (Beckman In	struments, Full -
1.			3
2	15		regression line
530 (56 , : =319 : 211)	t _{1/2}		ISI
(body mass index, BMI)	(insulin sensitivity inde	ev rate cons	
가 ;	glucose disappearance		
(under-weight, UW): 18.5 kg/m ² ,		3/t _{1/2} * 100 ((%/min)
(normal-weight, NW): 18.5~24.9 kg/m², (over-	ISI 2.5%/min	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(707)
weight, OW): 25~29.9 kg/m², (obese, OB: 30 kg/m²).	5)		
2.	3)		
1)		10	
	,	1	,
가 /			c-peptide
. (%) impedance	(RIA kit, Daiichi, Japa	ın) (IF	RMA kit, Dain-
(Inbody 2.0, Biospace, Korea)	abot, Japan)	•	
	4)	•	ary artery ca-
2)	Icification, CAC)	
(insulin	Electron beam comp	outed tomogra	aphy (EBT, IM-

ATRON Ultrafast CT, USA)	38)
	(total abdominal fat area) .
R-R 80% EKG gate	(visceral fat
, 3mm	tissue) , (subcutaneous fai
40 , CAC	tissue)
. CAC Agatston	/ (visceral fat area/su-
(pixel: 0.5 mm²)	bcutaneous fat area, VSR) .
, CT number 130~	
199 HU (Hounsfield unit) 1 , 200~299 HU 2 ,	8)
300~399 HU 3 , 400 HU 4	SPSS for Windows, version 11.0
	. Students t-test one-way
5) (intima-media thick-ness, IMT)	ANOVA chi-square tests p 0.05
B-mode Toshiba SSA-270A	
(Toshiba, Japan) 7.5 MHz (Axial resolu-	
tion: 0.2 mm) .	
	1.
(far	530 (UW),
wall) 10 mm 가	(NW), (OW), (OB) 47
	(8.9%), 329 (62.1%), 133 (25.1%) 21 (3.9%)
Pignoli ^{34,35)}	
(leading edge)	
Multicenter Isradipine Diuretic Atherosclerosis Study	. / 가 가
(MIDAS) IMT 가 1.3 mm	0.82 ± 0.11 , 0.91 ± 0.20 , 0.97 ± 0.13 , 0.98 ± 0.14
plaque가	가 . 21.2±5.2%
36,37)	25.1±5.7%, 30.9±5.6%, 35.3±5.2%
	(Table 1).
6) - (ankle-brachial pressure	(14515-1).
index, ABPI)	(, ,)
Plethysmography (MVL, Modulab, Life Science Inc.	(, , ,) 가 (Table 1).
Greenwich. CT)	(Table 1).
	UW 135.2±21.1, NW 136.1±18.1, OW 139.9
	±23.2, OB 145.2±18.2 mmHg 가
7)	UW NW 가
CT Max II (General Electric	가 .
Co.)	
Hounsfield number가 -150 -50	가 (Table

Table 1. The Clinical and Biochemical Characteristics of Patients According to BMI

	UW	NW	OW	ОВ
Number	47	329	133	21
Sex (M:F)	27:20	202:127	78:55	12:9
Age (years)	53.2±11.8	57.2±12.1	57.4±11.1	57.4 ± 10.2
BMI (kg/m²)	17.2±1.1	22.5 ± 1.2^{a}	$26.7 \pm 1.3^{b,c}$	$30.4 \pm 1.1^{d,e,f}$
WHR	0.82 ± 0.11	0.91 ± 0.25^{a}	$0.97 \pm 0.13^{b,c}$	$0.98 \pm 0.14^{d,c}$
Fat (%)	21.2±5.2	25.1 ± 5.7^{a}	$30.9 \pm 5.6^{b,c}$	$35.3 \pm 5.2^{d,e,f}$
DM duration (years)	11.4±7.2	10.9 ± 6.2	10.6±7.2	10.2±6.4
Anti-hypotensive medication	6/47 (12.8%)	42/329 (12.8%)	23/133 (17.3%)	4/21 (9.0%)
Smoking	10/47 (21.3%)	77/329 (23.4%)	29/133 (21.8%)	5/21 (23.8%)
Nephropathy	16/47 (34.0%)	115/329 (35.0%)	48/133 (36.1%)	8/21 (38.1%)
Neuropathy	28/47 (59.6%)	197/329 (59.9%)	84/133 (63.2%)	14/21 (66.7%)
Retinopathy	18/47 (38.3%)	121/329 (36.8%)	53/133 (39.8%)	9/21 (42.9%)
Prevalence of CHD	2/47 (4.3%)	14/329 (4.3%)	6/133 (4.5%)	1/21 (4.8%)
Systolic BP (mmHg)	135.2±21.1	136.1±18.1	$139.9 \pm 23.2^{b,c}$	$145.2 \pm 18.2^{d,e,f}$
Diastolic BP (mmHg)	81.1±10.8	86.5±10.1	88.1±11.2	93.1 ± 10.2
T. cholesterol (mmol/L)	4.86 ± 0.88	5.18±1.08	5.15±0.81	5.48 ± 0.81
Triglyceride (nmol/L)	1.64 ± 0.58	1.97 ± 0.70^{a}	1.98±0.64 ^b	$1.93 \pm 0.86^{\circ}$
HDL-C (mmol/L)	1.28 ± 0.27	1.11 ± 0.29^{a}	1.10 ± 0.30^{b}	$1.08 \pm 0.34^{\circ}$
HbA1c (%)	10.0±2.3	9.3±2.1	9.1 ± 1.0	9.7 ± 2.2
Free fatty acid (nmol/L)	2.55 ± 0.93	2.27 ± 0.84^{a}	2.69 ± 1.14^{b}	$2.35 \pm 0.80^{d,e,f}$
Fibrinogen (g/L)	4.14±0.83	4.05 ± 0.81^{a}	4.21 ± 0.90^{b}	$3.99 \pm 0.81^{d,e,f}$
24-hr albumin (g)	4.04 ± 1.89	4.42 ± 2.32	4.62 ± 1.93	4.68 ± 1.84
C-peptide (µg/L)	1.45±1.02	1.51±2.01	1.77 ± 1.70^{b}	$1.99 \pm 2.02^{d,e,f}$
ISI (%/min)	2.45 ± 2.10	2.31 ± 2.11 ^a	1.97±1.90 ^b	$1.89 \pm 2.22^{d,e,f}$

Values are mean±SD. UW, under weight; NW, normal weight; OW, over weight; OB, obese; BMI, body mass index; WHR, waist hip ratio; DM, diabetes mellitus; CHD, coronary heart disease; BP, blood pressure; HDL-C, high density lipoprotein-cholesterol; ISI, insulin sensitivity index. a: UW vs. NW, p<0.05; b: UW vs. OW, p<0.05; c: UW vs. OB, p<0.05; d: NW vs. OW, p<0.05; e: NW vs. OB, p<0.05; f: OW vs. OB, p<0.05.

1). UW 1.64 ± 0.58 nmol/L (NW, 2.55 ± 0.93 , 2.27 ± 0.84 , 2.69 ± 1.14 , 2.351.97±0.70; OW, 1.98±0.64; OB, 1.93±0.86 mg/dL) ±0.80 nmol/L 가 UW 1.28±0.27 mmol fibrinogen 4.14±0.83, 4.05±0.81, 4.21±0.90, /L (NW, 1.11 $3.99 \pm 0.81 \text{ mg/dL } (p=0.04)$ ± 0.29 ; OW, 1.10 ± 0.30 ; OB, 1.08 ± 0.34 mg/dL). 24 HbA1c 가 C-peptide

Table 2. Comparison of Abdominal Fat and Thigh Muscle Areas by CT Scan Between the Insulin Resistance (IR) group and non insulin resistance (non-IR) according to insulin sensitivity index

	IR group	non-IR group	p-value
Number	39	41	
Sex (M:F)	23:16	24:17	NS
Age (years)	57.3±12.1	55.4±12.1	NS
BMI (kg/m²)	22.2±1.1	22.3±1.3	NS
Waist/hip ratio	0.95 ± 0.05	0.91 ± 0.05	0.02
Fat (%)	28.1±5.5	24.2±5.2	0.01
DM duration (years)	11.1±6.3	10.8±6.5	NS
Visceral fat area (cm²)	152.0±60.7	96.5±28.5	0.03
SQ fat area (cm ²)	184.2±84.5	126.9±59.7	0.05
Thigh muscle area (cm ²)	99.7±37.9	114.6±40.2	0.02
V/S ratio	0.94 ± 0.52	0.72 ± 0.17	0.01
V/M ratio	1.32 ± 0.38	0.86 ± 0.24	0.01

Values are mean±SD. IR; insulin resistance; BMI, body mass index; DM, diabetes mellitus; SQ, subcutaneous; V/S ratio, visceral fat area/subcutaneous fat area ratio; V/M ratio, visceral fat area/thigh muscle area

Table 3. The Comparison of Normal-Weight Patients With and Without Abdominal Obesity According to WHR; Median Values in Men-0.95 and Women-0.91

	N	1en (n=115)	Woi	men (n=100)		
	> 0.95	< 0.95	p-value	> 0.91	< 0.91	p-value
Number	75	40		61	39	
Age (years)	55.2±11.8	56.2±12.1	NS	58.3±11.1	57.4±10.2	NS
BMI (kg/m²)	22.8±1.1	22.4 ± 1.2	NS	22.7 ± 1.3	22.4±1.1	NS
Fat (%)	24.2 ± 5.2	21.1±5.7	0.01	28.2 ± 5.6	25.3 ± 5.2	0.02
DM duration (years)	10.3±7.2	10.9 ± 6.2	NS	11.1±7.2	10.2 ± 6.4	NS
Systolic BP (mmHg)	136.2±21.1	133.1±18.1	0.05	138.9 ± 23.2	132.2±18.2	0.05
Diastolic BP (mmHg)	85.1±10.8	83.5 ± 10.1	NS	86.1±11.2	85.1±10.2	NS
T. cholesterol (mmol/L)	4.98 ± 0.88	4.97 ± 1.08	NS	5.28 ± 0.81	5.25 ± 0.81	NS
Trighyceride (mmol/L)	2.06 ± 0.58	1.85 ± 0.70	0.03	2.05 ± 0.64	1.77 ± 0.86	0.01
HDL-C (mmol/L)	1.06 ± 0.26	1.67 ± 0.29	0.02	1.10 ± 0.30	1.26 ± 0.34	0.02
HbAlc (%)	9.0 ± 2.3	9.1 ± 2.1	NS	9.1 ± 1.0	9.0 ± 2.2	NS
Free fatty acid (nmol/L)	2.55 ± 0.93	2.27 ± 0.84	0.04	2.69±1.14	2.35 ± 0.80	0.03
Fibrinogen (g/L)	4.18 ± 0.83	3.53 ± 0.81	0.02	4.21 ± 0.91	3.99 ± 0.81	0.04
ISI (%/min)	2.01 ± 2.10	2.78±2.11	0.02	2.03 ± 1.90	2.57 ± 2.22	0.02

Values are mean±SD. BMI, body mass index; DM, diabetes mellitus; BP, blood pressure; T. cholesterol, total cholesterol; HDL-C, high density lipoprotein-cholesterol; ISI, insulin sensitivity index

		가	±2.02 mg/dL
(136.2±21.1 vs. 133.2±18		(Table 1).	UW NW
(138.9±23.5 vs. 132.2±18	mmHg, p=0.05)	ISI 2.45±	IS
가	mmHg, p=0.05)	0, 1.89±2.22%/min	2.10, 2.01±2.11, 1.97±1.90,
	,	2.5%/	
62%	65%,	UW 28%, NW	min
41% 34%		75%가	60%, OW 68%, OB 75°
		가	가 가
가 .		vs. OW, p<0.05; UW vs.	(UW vs. NW, p<0.05; UW vs.
		, p<0.05; NW vs. OB,	OB, p<0.05; NW vs. OW, p
	가 .	0.05).	p<0.05; OW vs. OB, p<0.0
2.0	가	ISI가 2.5%/min	가
'0 mmol/L (p=0.03),	±0.58 1.85±0.70	39	41 2.5%/min
77±0.86 mg/dL (p=0.01)	2.05±0.64 1.77	y)	CT (computed tomography)
1.0			
29 mg/dL (p=0.02), 1.	±0.26 1.67±0.29	가	가 기
4 mmol/L (p=0.02)	±0.30 1.26±0.34	(152.0±60.7 vs. 96.5	가 (
		(184.2±84.5 vs.	$\pm 28.5 \text{ cm}^2, p=0.03),$
가	HbA1c		$126.9 \pm 59.7 \text{ cm}^2, p=0.05)$
			가
±0.93 vs. 2.27±0.84 mg/dL,	(2.55±	0.2 cm ² , p=0.02)	(99.7±37.9 vs. 114.6±40.2
(2.69±1.14 vs. 2.35	0.04),	가	(Table 2).
.03). fibrinogen	0.80 nmol/L, p=0.0	(0.94 ± 0.52)	/
$(4.18\pm0.83 \text{ vs. } 3.53\pm0.83)$		/	vs. 0.72±0.17, p=0.01)
(4.21±0.91 vs. 3.99±0.	g/L, p=0.04)	±0.24, p=0.01)가	$(1.32\pm0.38 \text{ vs. } 0.86\pm0$
	mg/dl, p=0.04)		가
	(Table 3).		-
1			(r=0.89, p=0.001)
0 vs. 2.78±2.11 mg/dL, p=0.0	가 (2.01±2.10		2. /
vs. 2.57±2.22 mg/dL, p=0.02)	(2.03±1.90 v		
	3.	-	가
	-	가 0.95	
가 NW			0.91 .
		(Table 3).	,
(1.()4+().29 vs ().89+0			
(1.04±0.29 vs. 0.89±0.3	mm, p<0.05), OW	£5.2% vs. 21.1±5.2%,	(24 2+5




Fig. 1. The comparison of IMT in subjects between NW group and OW group with or without abdominal obesity. * : P < 0.05, compared to subjects without abdominal obesity in NW group; ** : P < 0.05, compared to subjects without abdominal obesity in OW group




Fig. 2. The comparison of ABPI in subjects between NW group and OW group with or without abdominal obesity. * : P < 0.05, compared to subjects without abdominal obesity in NW group; ** : P < 0.05, compared to subjects without abdominal obesity in OW group




Fig. 3. The comparison of coronary artery calcification score measured by EBT between NW group and OW group with or without abdominal obesity. *: P < 0.05, compared to subjects without abdominal obesity in NW group; **: P < 0.05, compared to subjects without abdominal obesity in OW group

```
0.90 \pm 0.17 mm, p<0.05).
                                         NW
                                                  OW
                                                             mm, p<0.05), OW
                                                                                                             (282 \pm
                           가
                                                                                                       NW
                                                                                                                OW
                                                             215 vs. 132±178 mm, p<0.05).
                                                                                                        가
                                             (Fig. 1).
                                   가
                                                NW
                                                                  (Fig. 3).
  (1.01\pm0.09 \text{ vs. } 1.07\pm0.06 \text{ mm, p}<0.05), \text{ OW}
                         (1.03\pm0.05 \text{ vs. } 1.10\pm0.05
                                 OW
mm, p<0.05).
                       NW
         가
                   (Fig. 2).
                                                                                               (
                                                                                                              ),
                                                                                                                   2
                        가
                                     NW
                                                (1.00)
                                                                    2)
                                                                                  3)
±0.05 vs. 1.05±0.08 mm, p<0.05), OW
                                                                                                                   4
             (0.99\pm0.06 \text{ vs. } 1.06\pm0.07 \text{ mm, p} < 0.05).
             NW
                                                                  (odds ratio)
                      OW
가
                                                                                              2~4,11,39~41)
                  (Fig. 2).
  EBT
                                                                                        2
   가
                NW
                           (331±229 vs. 112±106
```

가 50% 46,47) 가 가 48) 가 60% 42). 2 32) Hales ISI 2.5%/min 5). 2 가 (thrifty phenotype hypothesis) 가 가 43,44) 가 가 가 가 70%가 가 2 가 20~25 kg/m² 가 가 60% Welborn 1966 가 가 80 200 mg/dL mg/dL 가 140 (14 U/mL) 가, mg/dL 51,52) 105 mg/dL 8 314 U/mL 가

가				7)	62)						
					;	가					
			가				가				
フ	ŀ	, 8,9)							-		16)
	1			가					가		10,
	,					가		17)	•		
		50%					,		2		
53	3,54)		가								
					,						
F00/	200/			50 0/							
59% 35%	38%	,		58%							
33 /0								•			
가		-									
가 ,				-		:	2				
4.55, 57)										가	
1,55~57)										/	
								가			
가						2		* I	•		
10,11,58)					,				,		
								/			
	,										
			,	,							
,	,										
					2		530	(26~8	25	56)	
			•		2	(bodv	mass i			30)	フ
						(4 - 4.)		5 kg/m			
		1,59)			18.5~2	4.9 kg/m			29.9 kg/r	n², :	30
					kg/m²			8.9%	6, 62.1%	5, 25.1%)
40, 45,00)		가			3.9%				가		
12~15,60)			B-mode		,				0.4.03		
					(coro	nary arte	ery calc				
61)					IMT)	_				thickne ial press	

index, ABPI)										
		(Kitt	, %/min)							
가 .				1. Re	aven GN	1: Role	of insulin	resistal	nce in i	hum -
: 1.			,	an	diseas	e. Diab	etes 37	:1595 -	1607,	1988
	HbA1c			2.	,	,	,	,	,	,
	/				,	,	,	,	,	,
					:					
		가			22:84 -	92, 19	98			
	フ	ŀ		3.	,	,	,	,	,	,
		,	,		,	,	:			
fibrinogen,	c-peptide		가				•	23:7	0 - 78,	1999
•				4.	,	,	,	,	,	,
	ISI				,	•				,
			%/min				/	().	
	UW	28%,	NW	_	5	5 (Supp	ol. 1):S1	17, 19	98	
60%, OW	68%, OB	75%		5.	,	,	,	,	,	,
가 가		가			, _	,	,	,	:	
가		/			フ				_	
	/	가			•	22	:199-20	1990	8	
가	•			6.	,	,	,	,	,	,
2.		-			,	,	:			
71	0.95	(0.91		100 10	0.5			75	9:153
가		111 44			162, 19.	95				
,	71	, HbA1	С	7.	,	,	,	,	,	,
	가		,		,	:				
, £:b-=:	1.:44	,				40	.010 0	20 100	_	
, fibrinogen	kitt	가	•	0		49	:819-82	20, 199	9	
3.	, ・ フ	- L N	1W	8.	,	,	,	,	,	,
	NW	י די			,	,	,	,	,	14:
OW	INVV	가	Γ	5.6	5-63, 1	000		•		14.
, OW . NW	OW	71	가	9.						
	Ovv		71				,	,	,	,
· :					,		peptide	,		
•		가			, 5:975-9				•	
	7	→r } .								
	,				,		,	,	,	,
	가				,	•				
	* I					49	:819-82	28. 1 <u>9</u> 9	5	•

11.	,	,	,	,	,	,
	,	:				
	18.	25 - 30	1994			•
40	70.2	20 00,	1004			
12.	,	,	,	,	,	,
	,	:				
		2	20:291 -	· <i>302, 1</i>	996	
13.	,	,	,	,	,	:
				25: <i>9</i> 6	60 <i>-966</i> ,	1995
14.	,	,	:			
				28:74	0 - 748,	1998
15.	,		,			
		26:35	-43, 19	96		
16.	,	,	,	,	,	,
	,	,	,	,	,	,
				thysmog		
	,		가 <i>N</i> /		-1)	
		23.1	12-180	0, 1999		
17.	,	,	,	,	,	,
	,	,	,	,	,	,
	,	,	,	,	:	
		56	S:317-3	28, 19	99	
18	Reaven GN					./ Inf

11

- 18. Reaven GM: Syndrome X: 6years later. J Int Med 236:13-22, 1994
- 19. World Health Organization Pacific Region: International Association for the study of obesity:
 International Obesity Task Force: Zimmet P,
 Inoue S: The Asia-Pacific perspective: Redefining Obesity and its Treatment, 1999
- Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S: The metabolically obese, normal-weight individual revisited. Diabetes 47:699-713, 1998
- 21. Tokugana K, Matsuzawa Y, Ishikawa K, Tarui S: A novel technique for the determination of the body fat by computed tomography. Int J Obes

- 7:437-445. 1983
- 22. Tarui S, Fujioka S, Tokunaga K, Matsuzawa Y: Comparison of pathophysiology between subcutaneous type and visceral type obesity, in Bray GA, LeBlanc J, Inoue S, Suzuki M(eds): Diet and Obesity. Tokyo, Japan Scientific Societies Press, p 143-152, 1988
- 23. Fuiioka S, Matsuzawa Y, Tokunaga K, Tarui S: Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36:54-59, 1987
- Nakajima T, Fujioka S, Tokunaga K, Matsuzawa Y, Tarui S: Correlation of intraabdominal fat accumulation and left ventricular performance in obesity. Am J Cardiol 64:369-373, 1989
- Kanai H, Matsuzawa Y, Katoni K, Keno K, Kobatake T, Nagai Y, Fujioka S Tokunaga K, Tarui S: Close observation of intra-abdominal fat accumulation to hypertension in obese women. Hypertension in obese women. Hypertension 16: 484-490, 1990
- Ferranini E, Barrett EJ, Bevilacqua S, Defronzo RA: Effects of fatty acids on glucose production and utilization in man. J Clin Invest 72:1737-1747, 1983
- 27. Boden G: Fatty acids on insulin resistance. Diabetes Care 19:394-395, 1996
- Svedberg J, Bjortorp P, Smith U, Lonroth P: Smith U, Lonroth P: Free-fatty acid inhibition of insulin binding, degradation and action in isolated rat hepatocyte. Diabetes 39:570-574, 1990
- Bevilacqua S, Bonadonna R, Buzzigoli G, Boni C, Ciociaro D, Maccari F, Giorico MA, Ferranini E: Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metabolism 36:570-574, 1990
- 30. Lewis GP, Steiner G: Acute effects of insulin in the control of LVDV production in humans: implications for the insulin-resistance state. Dia-

- betes Care 19:390-393, 1996
- 31. Garg A: Insulin resistance in the pathogenesis of dyslipidemia. Diabetes Care 19:387-389, 1996
- Hirst S, Phillips DI, Vines SK., Clark PM, Hales CN: Reproducibility of the short insulin tolerance test. Diabetic Med 10:839-842, 1993
- Agatston AS, Janowitz WR, Mildmer FJ: Quantification of coronary artery calcium using ultrafast computed tomography. J Am Cardiol 15:827, 1990
- 34. Pignoli P, Tremoli E, Oreste P, Poretti R: *Inti-mal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation* 74:1399-1406, 1986
- 35. Pignoli P: *Ultrasound B-mode imaging for arterial* wall thickness measurement. Atherosclerosis Rev 12:177-184, 1984
- Furberg CD, Byington RP, Borhani NA: Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). Am J Med 86:37-39, 1989
- Bond MG, Wilmoth SK, Enevold GL, Strickland HL: Detection and monitoring of asymptomatic atherosclerosis trials. Am J Med. 86:33-36, 1989
- 38. Ashwell M, Cole TJ, Dixon AK: New insight into the anthropometric classification of fat distribution shown by computed tomography. Br Med J 290:1692-1694, 1985
- 39. Welborn TA, Wearne K: Coronary disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 2:154-160, 1979.
- 40. Pyorala K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: Results from two population studies in Finland. Diabetes Care 2:131-141, 1979
- 41. Ducimetiere P, Eschwegw E, Papoz L, Richard JL, Claude JR, Rosselin G: *Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality*

- in a middle aged population. Diabetologia 19: 205-210. 1980
- 42. Yip J, Facchini FS, Reaven GM: Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 83:2773-2776. 1998

- 45. Huh KB: The role of insulin resistance in Korean patients with metabolic and cardiovascular disease. In: Huh KB, Shin SH, Kaneko T eds. Insulin Resistance in Human disease. p 7-12, Amsterdam, Experta Medica, 1993

- 48. , , , , , , ,

. 16:35-43,

49. Hales CN, Barker DJP: Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 35:595-601, 1992

1992

- 50. Welborn TA, Breckenridge A, Rubinstein AH, Dollaey CT, Russel FT: Serum insulin in essential hypertension and in peripheral vascular disease. Lancet 7451:1336-1337, 1966.
- 51. Chen Y-DI, Reaven GM: Insulin resistance and atherosclerosis. Diabetes Reviews 5:331-342, 1997
- 52. Reaven GM: Syndrome X, past, present and future. In: Draznin B, Rizza R, eds. Clinical research in diabetes and obesity, p357-382, Humana Press, Totowa, New Jersey 1997

- 53. Pollare T, Lithell H, Berne C: *Insulin resistance* is a characteristic feature of primary hypertension independent of obesity. Metabolism 39:167-174, 1990
- Zavaroni I, Mazza S, DallAglio E, Gasparini P, Passeri M, Reaven GM: Prevalence of hyperinsulinemia in patients with high blood pressure. J Intern Med 231:235-240, 1992
- 55. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194, 1991
- Kaplan NM: The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149:1514-1520, 1989
- 57. Davidson MB: Clinical implications of insulin resistance syndromes. Am J Med 99:420-426, 1995
- 58. Park SW, Song MK, Han SH, Cha BS, Song

- YD, Lee HC, Huh KB: Relationship between insulin resistance and plasma lipid levels in healthy young men (Abstract). Diabetes 47(Suppl. 1):A427. 1998
- 59. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of longterm complication in insulin-dependent diabetes mellitus. N Eng J Med 329:977-986, 1993
- 60. Huh KB, Lee HC, Cho SY, Lee JH, Song YD: The role of insulin resistance in Korean patients with coronary atherosclerosis. Diabetes 45(Suppl. 3):S59-S61, 1996
- Salonen JT, Salonen R: Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation (Suppl. 2) 87:55-65, 1993
- 62. Grobbee DE, Bots ML: Carotid intima-media thickness as an indicator of generalized atherosclerosis. J Int Med 236:567-573, 1994